💨 Abstract

Deputy President Paul Mashatile highlighted the potential of Lenacapavir, a long-acting injectable HIV prevention method approved in South Africa. Administered twice a year, it offers six months of protection and is seen as a significant advancement in HIV prevention, especially for vulnerable groups like young women and key populations facing stigma. Mashatile emphasized its practicality and discretion, aligning with the daily realities of people's lives.

Courtesy: Nereesha Patel